AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7766795 — intervention group
Group type: COMPARATOR
Intervention: Likelihood ratio test for cancer screening trials
Number of subjects: 0
Study 7766795 — intervention group
Group type: COMPARATOR
Intervention: Likelihood ratio test
Number of subjects: 0
Study 2495220 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined enteral nutrition (nasogastric tube feeding)
Number of subjects: 26
Study 2495220 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous oral intake (control group)
Number of subjects: 26
Study 2495220 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined enteral nutrition
Number of subjects: 26
Study 337144 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction program (Group I and Group IIa)
Number of subjects: 83
Study 337144 — intervention group
Group type: COMPARATOR
Intervention: No dietary program (Group IIb)
Number of subjects: 83
Study 30860409 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 22
Study 30860409 — intervention group
Group type: COMPARATOR
Intervention: Control (no Kinesio Taping)
Number of subjects: 22
Study 31867652 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing nicotine reduction as cigarettes no longer relieved cravings
Number of subjects: 1198
Study 31867652 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing nicotine reduction as cigarettes changed so that you would be able to quit more easily
Number of subjects: 1198
Study 31867652 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing nicotine reduction as nicotine levels were reduced by 95%
Number of subjects: 1198
Study 31867652 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing nicotine reduction as the government reduced nicotine levels by 95%
Number of subjects: 1198
Study 31867652 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing nicotine reduction as cigarettes were no longer addictive
Number of subjects: 1198
Study 28007331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin 5 mg/ezetimibe 10 mg, rosuvastatin 10 mg/ezetimibe 10 mg, rosuvastatin 20 mg/ezetimibe 10 mg)
Number of subjects: 245
Study 28007331 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (rosuvastatin 5 mg, rosuvastatin 10 mg, rosuvastatin 20 mg)
Number of subjects: 245
Study 28007331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 245
Study 28007331 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 245
Study 25997043 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified anthocyanin (320 mg/d)
Number of subjects: 74
Study 25997043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23537967 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital administration of ticagrelor 180 mg followed by matching placebo in hospital
Number of subjects: 1770
Study 23537967 — intervention group
Group type: COMPARATOR
Intervention: Prehospital administration of placebo followed by ticagrelor 180 mg in hospital
Number of subjects: 1770
Study 23537967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily for 30 days (for all patients)
Number of subjects: 1770
Study 20561768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (IPT-cog)
Number of subjects: 32
Study 20561768 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitative interventions
Number of subjects: 32
Study 19802534 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenshao Tablet (SST)
Number of subjects: 66
Study 19802534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16426085 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (50 units/axilla)
Number of subjects: 40
Study 16426085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16426085 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 40
Study 15297779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily in the morning
Number of subjects: 338
Study 15297779 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily in the evening
Number of subjects: 338
Study 11531680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil 0.3 microg.kg(‐1)
Number of subjects: 86
Study 11531680 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (control)
Number of subjects: 86
Study 9258989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine fumarate (40, 80, or 160 mg)
Number of subjects: 0
Study 9258989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9258989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine
Number of subjects: 0
Study 7506841 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 327
Study 7506841 — intervention group
Group type: COMPARATOR
Intervention: Dextran-70
Number of subjects: 327
Study 3474889 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic force applied via coil spring between maxillary premolars
Number of subjects: 0
Study 3474889 — intervention group
Group type: COMPARATOR
Intervention: Control group (premolars extracted without orthodontic force)
Number of subjects: 0
Study 28703421 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with supportive treatment
Number of subjects: 18
Study 28703421 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment only
Number of subjects: 18
Study 27143144 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental NEAT intervention plus mobile text message coaching (early texting group, n = 27)
Number of subjects: 40
Study 27143144 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental NEAT intervention plus mobile text message coaching (delayed texting group, n = 13)
Number of subjects: 40
Study 27143144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 24675203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin
Number of subjects: 46
Study 24675203 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefazolin
Number of subjects: 46
Study 24675203 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (cefazolin and vancomycin)
Number of subjects: 46
Study 24675203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with more severe infections
Number of subjects: 46
Study 22699036 — intervention group
Group type: COMPARATOR
Intervention: 15 mg nitroglycerin
Number of subjects: 0
Study 22699036 — intervention group
Group type: COMPARATOR
Intervention: 30 mg nitroglycerin
Number of subjects: 0
Study 22699036 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lidocaine + 30 mg nitroglycerin
Number of subjects: 0
Study 22699036 — intervention group
Group type: COMPARATOR
Intervention: 40 mg lidocaine + 30 mg nitroglycerin
Number of subjects: 0
Study 22699036 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine + placebo
Number of subjects: 0
Study 19320851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 320 μg
Number of subjects: 28
Study 19320851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 375 μg
Number of subjects: 28
Study 19320851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18339441 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievers (maintained glucose levels below 8mmol/L)
Number of subjects: 234
Study 18339441 — intervention group
Group type: COMPARATOR
Intervention: Non‐Achievers (did not maintain glucose levels below 8mmol/L)
Number of subjects: 234
Study 16230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide, 10 microg twice daily
Number of subjects: 551
Study 16230722 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine, 1 daily dose titrated to maintain fasting blood glucose levels of less than 5.6 mmol/L (<100 mg/dL)
Number of subjects: 551
Study 12235557 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexchlorpheniramine
Number of subjects: 20
Study 12235557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9917780 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic intraocular lens
Number of subjects: 81
Study 9917780 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lens
Number of subjects: 81
Study 9917780 — intervention group
Group type: COMPARATOR
Intervention: PMMA intraocular lens
Number of subjects: 81
Study 8562293 — intervention group
Group type: EXPERIMENTAL
Intervention: Litoxetine (twice daily for 4 days)
Number of subjects: 0
Study 2405742 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of platelet‐poor plasma (PPP)
Number of subjects: 45
Study 2405742 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of platelet‐rich plasma (PRP)
Number of subjects: 45
Study 2405742 — intervention group
Group type: COMPARATOR
Intervention: No plasmapheresis (control group)
Number of subjects: 45
Study 6988006 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid treatment (betamethasone)
Number of subjects: 0
Study 6988006 — intervention group
Group type: COMPARATOR
Intervention: Placebo/untreated group
Number of subjects: 0
Study 6988006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bèta‐adrenergic drugs (orciprenaline)
Number of subjects: 0
Study 6988006 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged ruptured membranes
Number of subjects: 0
Study 31823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP intra-articular injection (Group A)
Number of subjects: 180
Study 31823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (Group B)
Number of subjects: 180
Study 31823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy combined with autologous PRP injection (Group C)
Number of subjects: 180
Study 31823552 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study 29089344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 8966
Study 29089344 — intervention group
Group type: COMPARATOR
Intervention: No Diabetes Mellitus
Number of subjects: 8966
Study 25273923 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking without optic flow (Ganzfeld goggles)
Number of subjects: 0
Study 25273923 — intervention group
Group type: COMPARATOR
Intervention: Normal vision (control group)
Number of subjects: 0
Study 24315046 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 96
Study 24315046 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 96
Study 22978595 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric rhizome powder (TRP) 25 g/kg
Number of subjects: 320
Study 22978595 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric rhizome powder (TRP) 50 g/kg
Number of subjects: 320
Study 22978595 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric rhizome powder (TRP) 75 g/kg
Number of subjects: 320
Study 22978595 — intervention group
Group type: COMPARATOR
Intervention: Turmeric rhizome powder (TRP) 0 g/kg (Control)
Number of subjects: 320
Study 20003205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (Hyalubrix) injections
Number of subjects: 42
Study 20003205 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic (mepivacaine)
Number of subjects: 42
Study 17154678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pholcodine
Number of subjects: 129
Study 17154678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 129
Study 12875478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg o.d.
Number of subjects: 1882
Study 12875478 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 12.5 mg o.d.
Number of subjects: 1882
Study 12875478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Lacidipine and Chlorthalidone)
Number of subjects: 1882
Study 10383520 — intervention group
Group type: EXPERIMENTAL
Intervention: LTdbCA (lansoprazole 30 mg b.d., tri-potassium dicitrato bismuthate one tablet b.d., clarithromycin 250 mg b.d., amoxycillin 1 g b.d. for 3 days)
Number of subjects: 180
Study 10383520 — intervention group
Group type: EXPERIMENTAL
Intervention: RbcCA (ranitidine bismuth citrate 400 mg b.d., clarithromycin 250 mg b.d., amoxycillin 1 g b.d. for 3 days)
Number of subjects: 180
Study 10383520 — intervention group
Group type: COMPARATOR
Intervention: OCM (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. for 1 week)
Number of subjects: 180
Study 9546929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 687
Study 9546929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 1829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-impregnated prosthesis
Number of subjects: 41
Study 1829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimpregnated prosthesis
Number of subjects: 41
Study 1829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortoiliac reconstruction
Number of subjects: 41
Study 1829489 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomies (control)
Number of subjects: 41
Study 1829489 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vascular disease
Number of subjects: 41
Study 1829489 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 41
Study 6342133 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin (20 mg/day)
Number of subjects: 48
Study 6342133 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (100 mg/day)
Number of subjects: 48
Study 6342133 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 48
Study 6342133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31754170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (Bafa Wubu of Tai Chi)
Number of subjects: 36
Study 31754170 — intervention group
Group type: EXPERIMENTAL
Intervention: General aerobic exercise (brisk walking)
Number of subjects: 36
Study 31754170 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 30497202 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant granulocyte colony-stimulating factor
Number of subjects: 0
Study 30497202 — intervention group
Group type: COMPARATOR
Intervention: Classic surgical and rehabilitative treatments
Number of subjects: 0
Study 27267503 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy-weight gain (IPT-WG)
Number of subjects: 6
Study 25424573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5.1 hours/night for 8 days/8 nights)
Number of subjects: 16
Study 25424573 — intervention group
Group type: COMPARATOR
Intervention: Usual sleep (6.9 hours/night for 8 days/8 nights)
Number of subjects: 16
Study 25424573 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-groups comparison
Number of subjects: 16
Study 25424573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-flow mediated vasodilatation (NFMD)
Number of subjects: 16
Study 22064208 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at doses of 0.44, 1.3, or 2.7 g/d
Number of subjects: 131
Study 19558344 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement
Number of subjects: 16
Study 19558344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17955441 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 590
Study 17955441 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal conjugate vaccine (MCV)
Number of subjects: 590
Study 16361050 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 140
Study 16361050 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 140
Study 12084664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO(2)
Number of subjects: 14
Study 12084664 — intervention group
Group type: COMPARATOR
Intervention: Room air inhalation
Number of subjects: 14
Study 9708611 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1 g administered orally before and after hemodialysis treatments)
Number of subjects: 101
Study 9708611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered orally before and after hemodialysis treatments)
Number of subjects: 101
Study 7609274 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (200 to 250 micrograms/kg/d)
Number of subjects: 26
Study 7609274 — intervention group
Group type: COMPARATOR
Intervention: No-Iron (total parenteral nutrition without iron)
Number of subjects: 26
Study 2227819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg/day) for 5 weeks
Number of subjects: 15
Study 2227819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 660211 — intervention group
Group type: EXPERIMENTAL
Intervention: Once or twice a day dosage regimens of phenytoin
Number of subjects: 0
Study 660211 — intervention group
Group type: COMPARATOR
Intervention: More frequent regimens of phenytoin
Number of subjects: 0
Study 30942029 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular gold-needle therapy
Number of subjects: 120
Study 30942029 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point pressure therapy
Number of subjects: 120
Study 30942029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herb group
Number of subjects: 120
Study 30942029 — intervention group
Group type: COMPARATOR
Intervention: Health control group
Number of subjects: 120
Study 29125542 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly digestible starch (SDS) in an instant pudding
Number of subjects: 14
Study 29125542 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly digestible starch (SDS) in a cold-pressed bar
Number of subjects: 14
Study 29125542 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study 26133284 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with LAA closure
Number of subjects: 89
Study 26133284 — intervention group
Group type: COMPARATOR
Intervention: PVI-only
Number of subjects: 89
Study 23933422 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based caregiver-training program
Number of subjects: 129
Study 23933422 — intervention group
Group type: COMPARATOR
Intervention: Control group (written instructions and social telephone follow-ups)
Number of subjects: 129
Study 21689269 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM-based program for breastfeeding mothers
Number of subjects: 476
Study 21689269 — intervention group
Group type: COMPARATOR
Intervention: Control (usual post-natal care)
Number of subjects: 476
Study 19193267 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical masks
Number of subjects: 286
Study 19193267 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐fit‐tested P2 masks
Number of subjects: 286
Study 19193267 — intervention group
Group type: COMPARATOR
Intervention: No masks
Number of subjects: 286
Study 16806625 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 49
Study 16806625 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 49
Study 16806625 — intervention group
Group type: COMPARATOR
Intervention: Conventional agents
Number of subjects: 49
Study 16806625 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine or Olanzapine
Number of subjects: 49
Study 14602781 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg E2 alone
Number of subjects: 24
Study 14602781 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg E2 combined with oral dydrogesterone (20 mg/d) during the last 14 days
Number of subjects: 24
Study 11252656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium prophylaxis
Number of subjects: 0
Study 8775337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine fumarate
Number of subjects: 120
Study 8775337 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 120
Study 8775337 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120
Study 8775337 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drugs (Control)
Number of subjects: 120
Study 1599061 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural 0.2% bupivacaine combined with fentanyl
Number of subjects: 30
Study 1599061 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural 0.2% bupivacaine alone
Number of subjects: 30
Study 1599061 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural fentanyl alone
Number of subjects: 30
Study 1599061 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 30
Study 6562990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of oestriol tablets (1 to 3 mg daily for 1 or more cycles)
Number of subjects: 81
Study 31421665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga training (60 minutes per session, 3 times per week for 8 weeks)
Number of subjects: 27
Study 31421665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga training
Number of subjects: 27
Study 31421665 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal activities)
Number of subjects: 27
Study 31500690 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 60,000 IU weekly for 2 weeks (insufficient levels) or 6 weeks (deficient levels)
Number of subjects: 71
Study 31500690 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance supplements of 1,000 IU/day for those with normal serum 25(OH)D levels
Number of subjects: 71
Study 30290685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 400 IU/day
Number of subjects: 0
Study 30290685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/day
Number of subjects: 0
Study 26857706 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care plus chiropractic care
Number of subjects: 750
Study 26857706 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 750